Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,023 across all filing types
Latest filing 2023-07-27 Interim / Quarterly Rep…
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
UCB Half-Year 2023 Report - EN - final.pdf
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled '2023 Half-Year Financial Report' and contains comprehensive financial statements, including a condensed consolidated income statement, statement of financial position, cash flow statement, and notes to the accounts for the six-month period ended 30 June 2023. It also includes a business performance review and a statutory auditor's review report. This meets the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H1 2023
2023-07-27 English
2023_Half-Year_Report-FR.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a 'Rapport de gestion du premier semestre 2023' (Management Report for the first half of 2023) for UCB. It contains comprehensive financial statements, including consolidated income statements, balance sheets, cash flow statements, and detailed notes to the financial statements for the six-month period ending June 30, 2023. It also includes an auditor's review report. Since it covers a period shorter than a full fiscal year and contains substantive financial data and analysis, it is classified as an Interim/Quarterly Report. H1 2023
2023-07-27 French
2023_Half-Year_Report-NL.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a 'Halfjaarlijks Financieel Verslag 2023' (Half-Yearly Financial Report 2023) for UCB. It contains comprehensive financial statements, including a consolidated income statement, balance sheet, cash flow statement, and detailed notes for the six-month period ending June 30, 2023. It also includes a management review of performance and an auditor's review report. As it covers a period shorter than a full fiscal year and contains substantive financial data, it is classified as an Interim/Quarterly Report. H1 2023
2023-07-27 Dutch
UCB PR rozanolixizumab FDA approval June 27 2023 ENG.pdf
Regulatory Filings Classification · 100% confidence The document is a press release dated June 27, 2023, announcing that the U.S. FDA has approved RYSTIGGO® (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG). It details the approval, efficacy data from the MycarinG study, safety information, and commercial availability timeline (Q3 2023). This type of announcement, which communicates key financial/product milestones and results (in this case, a major regulatory approval), aligns best with an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it focuses on the immediate, material news of a product approval and includes key data points, it functions as an initial announcement of a significant event, similar to an earnings release highlighting key results. However, given the specific context of a major drug approval announcement, it is often categorized as a general regulatory/material event announcement. Since 'Earnings Release' (ER) is defined as 'Initial announcement of quarterly/periodical financial results (key highlights only)', and this is an announcement of a regulatory milestone with key data, it fits the spirit of an ER more closely than a general 'RNS' or a comprehensive 'IR'. If a specific 'Regulatory Approval Announcement' code existed, it would be preferred, but among the given options, ER captures the nature of a time-sensitive, material highlight announcement best, although RNS is a strong secondary candidate as a general regulatory filing.
2023-06-27 English
Regulated Inside - 26.06.23.pdf
Regulatory Filings Classification · 95% confidence The document is titled with a company update regarding a regulatory submission ('UCB Provides Update on U.S. FDA Review of the Biologics License Application for Bimekizumab'). It uses the header 'Regulated Information – Inside Information' and is dated June 26, 2023. It discusses FDA review timelines, approvals in other jurisdictions, and confirms financial guidance. This format is characteristic of a press release announcing material, non-public information, often related to regulatory or operational milestones, which typically falls under general Regulatory Filings (RNS) or sometimes an Earnings Release (ER) if it contained financial results. Since it is an update on a specific regulatory process (BLA review) and includes forward-looking statements and contact information typical of a press release, the most appropriate general category for this type of announcement, which is not a formal financial report (like 10-K or IR) or a call transcript, is Regulatory Filings (RNS). It is not a specific announcement like Director's Dealing, Dividend Notice, or Management Discussion & Analysis.
2023-06-26 English
230519 PR Transparency notification FMR LLC.pdf
Major Shareholding Notification Classification · 99% confidence The document is a 'Transparency notification' issued by UCB SA/NV announcing that FMR LLC's shareholding crossed the 3% threshold following an acquisition of voting securities. This type of filing, which reports changes in significant share ownership levels by an entity, directly corresponds to the definition of a Major Shareholding Notification (MRQ). The text explicitly details the date the threshold was crossed, the previous holding percentage, and the new holding percentage (4.37%).
2023-05-26 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.